Therapeutics News and Research

RSS

Engineering cell-based, biological devices may selectively kill cancer cells without disrupting healthy cells

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.

18 Apr 2014

XBiotech announces results from Phase I/II oncology study

XBiotech is announcing that results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston, TX were published today in Lancet Oncology. The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix™, XBiotech's novel, non-cytotoxic, anti-tumor therapy.

18 Apr 2014

Global cancer profiling market expected to grow $54.8 billion by 2018

Global Information Inc. announces the addition of a new market research report "Cancer Profiling and Pathways: Technologies and Global Markets" at GIIResearch.com.

18 Apr 2014

Agios begins AG-348 Phase 1 study to treat PK deficiency

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEM), today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers.

18 Apr 2014

Alcresta signs agreement with CFFT to support nutritional status of people with cystic fibrosis

Alcresta, a leading medical nutrition company developing innovative enzyme-based products for individuals with unique nutritional needs battling acute conditions or chronic diseases, today announced the company has signed an agreement with Cystic Fibrosis Foundation Therapeutics (CFFT) to accelerate the development of Alcresta's enzyme-based point-of-care products to support the nutritional status of people with cystic fibrosis (CF).

17 Apr 2014

Nora Therapeutics closes $18M Series B financing to expand drug development

Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing.

17 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Wilson Therapeutics closes $40 million Series B financing

Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP. The company's founding investor, HealthCap, also participated in the round.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

Anika Therapeutics reports first commercial sale of Monovisc in the U.S.

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, today announced the first U.S. commercial sale of Monovisc by its commercial partner, DePuy Synthes Mitek Sports Medicine, a leading orthopedic sports medicine company.

16 Apr 2014

Bioniche Life Sciences sells Animal Health business to Vétoquinol

Vétoquinol and Bioniche Life Sciences Inc., today jointly announced the closing of the sale of Bioniche's Animal Health business to Vétoquinol.

16 Apr 2014

TSRI announces formation of Scripps Advance

The Scripps Research Institute (TSRI) today announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates.

15 Apr 2014

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's promising projects, and which was recently published in the journal Nature Communications.

15 Apr 2014

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

Nanotechnology unlocks new pathways for targeted drug delivery

Significant advances have been made in chemotherapy over the past decade, but targeting drugs to cancer cells while avoiding healthy tissues continues to be a major challenge.

15 Apr 2014

ICB International develops tracer for imaging alpha-synuclein in Parkinson's disease

On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.

11 Apr 2014

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor Todd Bauer, MD, presented data at the 105th Annual Meeting of the American Association for Cancer Research (AACR), the premier cancer research event held in San Diego, California from April 5-9.

11 Apr 2014

Therapeutics News and Research

Engineering cell-based, biological devices may selectively kill cancer cells without disrupting healthy cells

XBiotech announces results from Phase I/II oncology study

Global cancer profiling market expected to grow $54.8 billion by 2018

Agios begins AG-348 Phase 1 study to treat PK deficiency

Alcresta signs agreement with CFFT to support nutritional status of people with cystic fibrosis

Nora Therapeutics closes $18M Series B financing to expand drug development

Iconic Therapeutics completes $20 million Series B-1 equity financing

Wilson Therapeutics closes $40 million Series B financing

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Anika Therapeutics reports first commercial sale of Monovisc in the U.S.

Bioniche Life Sciences sells Animal Health business to Vétoquinol

TSRI announces formation of Scripps Advance

Vivolux receives FDA clearance to proceed with phase I/II clinical trial of VLX600

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Nanotechnology unlocks new pathways for targeted drug delivery

ICB International develops tracer for imaging alpha-synuclein in Parkinson's disease

Tau Therapeutics presents data of T-type calcium channel inhibitors in treatment of pancreatic cancer

BioZorb 3D surgical marker improves ability to target radiation treatment for breast cancer

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News